This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Kim and colleagues¹ found elevated serum osteopontin levels in patients with ovarian carcinoma. While the authors' approach has high sensitivity, the nonspecific nature of osteopontin expression in many diseases limits the potential clinical application of serum osteopontin as a unique biomarker for ovarian cancer.

Test specificity is central to any biomarker or screening program. Osteopontin may be expressed in many inflammatory and noninflammatory diseases including cancers of varied tissue origin.^2-3 Although a variety of cell types express osteopontin, macrophages are a major source.² Even in carcinoma, there is evidence that infiltrating macrophages rather than tumor cells are the principal source of osteopontin.³ Prior investigations have shown very high levels of osteopontin in hemodialysis patients with arterial atherosclerosis and in patients with gram-negative sepsis.⁴ These studies suggest that assays of total serum osteopontin alone will lack sufficient specificity to be a clinically applicable cancer biomarker.

In contrast . . . [Full Text of this Article]

RELATED ARTICLES

Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Jae-Hoon Kim, Steven J. Skates, Toshimitsu Uede, Kwong-kwok Wong, John O. Schorge, Colleen M. Feltmate, Ross S. Berkowitz, Daniel W. Cramer, and Samuel C. Mok
JAMA. 2002;287(13):1671-1679.
ABSTRACT | FULL TEXT  

Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Yan Xu, Zhongzhou Shen, Donald W. Wiper, Minzhi Wu, Richard E. Morton, Paul Elson, Alexander W. Kennedy, Jerome Belinson, Maurie Markman, and Graham Casey
JAMA. 1998;280(8):719-723.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine
Ye et al.
Clin. Cancer Res. 2006;12:432-441.
ABSTRACT | FULL TEXT